Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke

• Status: Recruiting
• Trial end date: 2022-05-24
• Target enrollment: 0
• Participant gender: All

Summary

In non-acute symptomatic ischemic stroke, the decision-making of medical treatment plus intracranial stenting has been more and more popular, especially in patients with intracranial large severe stenosis or occlusive artery. Nonetheless, there is no evidence from randomized controlled trials evaluating the efficacy of this treatment after the Wingspan Stent System Post Market Surveillance (WEAVE) and Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN) trial compared with medical treatment alone. This trial was to investigate whether medical treatment plus intracranial stenting would prevent the recurrent ischemic stroke in the territory of the symptomatic intracranial artery during 1-year follow-up.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Can Tho Stroke International Services Hospital

Criteria

Inclusion Criteria:

• Evidence of intracranial large severe stenosis or occlusive artery in angiography.

• Absence of intracranial hemorrhage.

• Premorbid mRS score is ≤ 3.

• Recurrent stroke in the target territory during the medical treatment for ischemic stroke prevention.

Exclusion Criteria:

• Tandem lesion.

• Loss to follow-up after discharge.

• A severe or fatal combined illness before acute ischemic stroke.

• Progressive neurologic deficit within 7 days after acute ischemic stroke.

• Large middle cerebral artery infarct within 30 days after acute ischemic stroke.